CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Yarrow Bioscience Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Yarrow Bioscience Inc
470 James Street, Suite 007
Phone: (650) 486-1416p:650 486-1416 NEW HAVEN, CT  06513  United States Ticker: YARWYARW
Business Summary
Yarrow Bioscience, Inc. is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company is developing YB-101, an anti-thyroid stimulating hormone receptor (TSHR) monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both Graves' Disease (GD) and Thyroid Eye Disease (TED), offering a single targeted treatment to address both diseases. By blocking TSHR, the common target of autoantibodies in both the thyroid and the eye, YB-101 has the potential to rapidly arrest the disease process and provide improved efficacy and safety versus the standard of care and other mechanisms in development. YB-101 is designed for convenient subcutaneous administration, with the potential for infrequent dosing and future autoinjector presentations. The Company has initiated dosing in a Phase 2a/2b trial evaluating YB-101 in patients with GD, with or without concurrent TED.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202612/31/2025YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board BillLundberg 62 7/27/2026 7/27/2026
Chief Executive Officer, Director Rebecca V.Frey 52 7/27/2026 7/27/2026
Chief Financial Officer TylerZeronda 40 7/27/2026 6/18/2021
7 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Vyne Pharmaceuticals Ltd 7 Golda Meir Street, 3rd floor NESS-ZIONA Israel

Business Names
Business Name
MNLO
Name (Jurisdiction)
VYNE
VYNE Pharmaceuticals Inc. (Delaware)
YARW
Yellow Merger Sub Corp. (Delaware)

General Information
Number of Employees: 10 (As of 12/31/2025)
Outstanding Shares: 2,669,746 (As of 8/10/2026)
Shareholders: 7
Stock Exchange: NASD
Federal Tax Id: 453757789
Fax Number: (302) 655-5049


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, August 16, 2026